CKDXF (Opthea) Total Liabilities: $257.87 Mil (As of Jun. 2025)


What is Opthea Total Liabilities?

Opthea CKDXF Total Liabilities is $257.87 Mil as of Jun. 2025. The stock has 3 warning signs investors should review.

Opthea's Total Liabilities for the quarter that ended in Jun. 2025 was $257.87 Mil.

Opthea's quarterly Total Liabilities increased from Jun. 2024 ($264.60 Mil) to Dec. 2024 ($314.48 Mil) but then declined from Dec. 2024 ($314.48 Mil) to Jun. 2025 ($257.87 Mil).

Opthea's annual Total Liabilities increased from Jun. 2023 ($104.49 Mil) to Jun. 2024 ($264.60 Mil) but then declined from Jun. 2024 ($264.60 Mil) to Jun. 2025 ($257.87 Mil).

Opthea Total Liabilities Historical Data

* Premium members only.

The historical data trend for Opthea's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Opthea Total Liabilities Chart

Opthea Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.12 12.07 104.49 264.60 257.87

Opthea Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 104.49 213.41 264.60 314.48 257.87

Opthea Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Opthea's Total Liabilities for the fiscal year that ended in Jun. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=257.868+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=257.87

Total Liabilities=Total Assets (A: Jun. 2025 )-Total Equity (A: Jun. 2025 )
=56.799--201.069
=257.87

Opthea's Total Liabilities for the quarter that ended in Jun. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=257.868+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=257.87

Total Liabilities=Total Assets (Q: Jun. 2025 )-Total Equity (Q: Jun. 2025 )
=56.799--201.069
=257.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $257.87 Mil mean?
Opthea (CKDXF) has a Total Liabilities of $257.87 Mil as of Jun. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Opthea and its competitors.
Is Opthea's Total Liabilities too high?
Opthea's current Total Liabilities is $257.87 Mil.
How does Opthea's Total Liabilities compare to VRTX and REGN?
Opthea's Total Liabilities of $257.87 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Opthea and its competitors. Opthea's current Total Liabilities is $257.87 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Opthea stock overvalued right now?
Opthea (CKDXF) has a current Total Liabilities of $257.87 Mil. The current Total Liabilities is $257.87 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Opthea (CKDXF), the current Total Liabilities is $257.87 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Opthea Business Description

Address C/ Prime Company Compliance, 505 Little Collins Street, Level 9, Melbourne, VIC, AUS, 3000
Opthea Ltd is engaged in researching and developing novel therapeutic products that target Vascular Endothelial Growth Factors (VEGF) C, D, and R3. The Group operates in one industry and two geographical areas, namely biotechnology and healthcare, with operations in Australia and the United States. The company focuses on developing biological therapeutics for eye diseases and is currently developing a novel biologic therapy, OPT-302, for the treatment of eye conditions. Its products are based on an intellectual property portfolio covering VEGF-C, VEGF-D, and VEGF Receptor-3 targets, aimed at treating diseases associated with blood and lymphatic vessel growth and vascular leakage.